digital health companies glp-1 programs Noom Launches Microdose Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program Novo Nordisk seeks digital health

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later

2019;68:1810P

Bioscience Reports, [online] 41(5), p.BSR20210427

The studys methodology and findings revealed data points: Among 710 type 2 diabetes patients, 17 semaglutide users developed NAION versus only 6 non-users, despite similar baseline characteristics In the weight loss cohort of 979 patients, NAION occurred in 20 semaglutide users compared to 3 in the control group Cumulative NAION incidence over 36 months reached 8.9% for diabetic semaglutide users versus 1.8% for non-GLP-1 medications Weight loss patients showed 6.7% NAION incidence with semaglutide versus 0.8% without Manual chart review by neuro-ophthalmology specialists ensured diagnostic accuracy often lacking in larger database studies Risk persisted after controlling for known NAION risk factors including age, sex, hypertension, and sleep apnea The biological plausibility of semaglutide-induced NAION stems from multiple proposed mechanisms that researchers continue investigating